Virtus ETF Advisers LLC Rocket Pharmaceuticals, Inc. Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

A detailed history of Virtus ETF Advisers LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 4,028 shares of RCKT stock, worth $52,525. This represents 0.04% of its overall portfolio holdings.

Number of Shares

4,028

Previous 3,960 1.72%

Holding current value

$52,525

Previous $85,000 12.94%

% of portfolio

0.04%

Previous 0.04%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$17.6 - $25.88 $1,196 - $1,759	68 Added 1.72%	4,028 $74,000
Q2 2024 Aug 14, 2024	BUY	$20.66 - $26.72 $18,532 - $23,967	897 Added 29.29%	3,960 $85,000
Q1 2024 May 15, 2024	SELL	$26.16 - $30.74 $5,519 - $6,486	-211 Reduced 6.44%	3,063 $82,000
Q4 2023 Feb 15, 2024	SELL	$16.78 - $31.94 $18,155 - $34,559	-1,082 Reduced 24.84%	3,274 $98,000
Q3 2023 Nov 07, 2023	SELL	$15.07 - $24.05 $6,570 - $10,485	-436 Reduced 9.1%	4,356 $89,000
Q2 2023 Aug 14, 2023	BUY	$16.59 - $23.6 $5,823 - $8,283	351 Added 7.9%	4,792 $95,000
Q1 2023 May 15, 2023	SELL	$15.79 - $22.6 $27,048 - $38,713	-1,713 Reduced 27.84%	4,441 $76,000
Q4 2022 Feb 14, 2023	SELL	$15.5 - $22.76 $57,443 - $84,348	-3,706 Reduced 37.59%	6,154 $120,000
Q3 2022 Nov 14, 2022	BUY	$12.37 - $18.41 $841 - $1,251	68 Added 0.69%	9,860 $157,000
Q2 2022 Aug 12, 2022	BUY	$7.96 - $16.64 $23,880 - $49,920	3,000 Added 44.17%	9,792 $135,000
Q1 2022 May 16, 2022	SELL	$13.16 - $23.68 $5,264 - $9,472	-400 Reduced 5.56%	6,792 $108,000
Q4 2021 Feb 14, 2022	BUY	$21.52 - $36.02 $57,802 - $96,749	2,686 Added 59.61%	7,192 $157,000
Q3 2021 Nov 15, 2021	SELL	$27.42 - $48.97 $6,251 - $11,165	-228 Reduced 4.82%	4,506 $135,000
Q2 2021 Aug 10, 2021	SELL	$39.41 - $47.25 $24,710 - $29,625	-627 Reduced 11.7%	4,734 $210,000
Q1 2021 May 17, 2021	BUY	$43.34 - $65.91 $4,334 - $6,591	100 Added 1.9%	5,361 $238,000
Q4 2020 Feb 12, 2021	SELL	$23.3 - $59.57 $273,402 - $698,994	-11,734 Reduced 69.04%	5,261 $289,000
Q3 2020 Nov 13, 2020	SELL	$20.5 - $28.59 $47,457 - $66,185	-2,315 Reduced 11.99%	16,995 $389,000
Q2 2020 Aug 05, 2020	BUY	$13.32 - $22.61 $38,561 - $65,455	2,895 Added 17.64%	19,310 $404,000
Q1 2020 May 14, 2020	SELL	$9.71 - $25.11 $23,216 - $60,038	-2,391 Reduced 12.71%	16,415 $229,000
Q4 2019 Feb 13, 2020	BUY	$11.07 - $24.23 $34,793 - $76,154	3,143 Added 20.07%	18,806 $428,000
Q3 2019 Nov 12, 2019	SELL	$10.85 - $14.78 $9,461 - $12,888	-872 Reduced 5.27%	15,663 $182,000
Q2 2019 Aug 13, 2019	SELL	$15.0 - $19.81 $18,960 - $25,039	-1,264 Reduced 7.1%	16,535 $248,000
Q1 2019 May 14, 2019	SELL	$13.45 - $19.01 $24,277 - $34,313	-1,805 Reduced 9.21%	17,799 $312,000
Q4 2018 Feb 05, 2019	SELL	$11.21 - $23.53 $24,325 - $51,060	-2,170 Reduced 9.97%	19,604 $291,000
Q3 2018 Nov 14, 2018	SELL	$18.5 - $25.49 $295,556 - $407,228	-15,976 Reduced 42.32%	21,774 $536,000
Q2 2018 Aug 10, 2018	BUY	$14.58 - $23.0 $550,395 - $868,250	37,750 New	37,750 $741,000

Others Institutions Holding RCKT

# of Institutions

209

Shares Held

93.2M

Call Options Held

319K

Put Options Held

70.3K

View Full List

About ROCKET PHARMACEUTICALS, INC.

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $987M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

More about RCKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account

Virtus ETF Advisers LLC Rocket Pharmaceuticals, Inc. Transaction History